Habitrol, Nicoderm Cq, Nicotrol, Prostep (nicotine) is a small molecule pharmaceutical. Nicotine was first approved as Habitrol on 1996-03-22. It is used to treat tobacco use disorder and ulcerative colitis in the USA. It is known to target transient receptor potential cation channel subfamily A member 1, P2Y purinoceptor 11, hydroxycarboxylic acid receptor 1, neuronal acetylcholine receptor subunit alpha-4, hydroxycarboxylic acid receptor 2, transient receptor potential cation channel subfamily M member 2, potassium voltage-gated channel subfamily D member 3, neuronal acetylcholine receptor subunit alpha-9, hydroxycarboxylic acid receptor 3, neuronal acetylcholine receptor subunit alpha-10, and neuronal acetylcholine receptor subunit alpha-3. Rugby nicotine polacrilex gum, mint flavor's patent is valid until 2021-05-22 (FDA).
|Trade Name||Habitrol, Nicoderm Cq, Nicotrol, Prostep|
|Indication||tobacco use disorder, ulcerative colitis|